Results of the present study implied the roles of EGFR/MAP2K1/mTOR/YAP1 signaling pathways in the progression, therapeutic resistance, immune-invasive phenotypes, and worse prognoses of NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.